VORIFUNG 200 Tablet is a potent antifungal pharmaceutical formulation manufactured by BluepillExpress, developed to combat life-threatening fungal infections in both immunocompromised and critically ill patients. Each tablet contains 200 mg of Voriconazole, a second-generation triazole antifungal agent that works by inhibiting the fungal cytochrome P450–dependent enzyme lanosterol 14α-demethylase. This mechanism disrupts ergosterol synthesis, an essential component of the fungal cell membrane, leading to cell death and fungal clearance.

Voriconazole, the active ingredient in VORIFUNG 200 Tablet, exhibits excellent activity against a wide range of fungal pathogens including Candida species (including fluconazole-resistant strains), Aspergillus species, and emerging molds such as Fusarium and Scedosporium. It is particularly indicated for the treatment of invasive aspergillosis, serious Candida infections in non-neutropenic patients, esophageal candidiasis, and other deep tissue or bloodstream fungal infections where conventional antifungal agents may be inadequate.

VORIFUNG 200 is formulated for oral administration with enhanced bioavailability and absorption characteristics. The oral tablet achieves therapeutic serum concentrations rapidly and is considered bioequivalent to its intravenous formulation. This allows for flexible switching between IV and oral routes, improving patient compliance and reducing hospitalization costs. VORIFUNG is widely used in patients undergoing chemotherapy, transplant recipients, or those with advanced HIV/AIDS, where fungal infections pose a significant risk.

The product is manufactured under WHO-GMP-certified facilities with stringent in-process and post-production quality checks at BluepillExpress. Each batch undergoes comprehensive testing for potency, dissolution, microbial limits, and stability, ensuring international standards for safety and efficacy. The tablets are film-coated for protection from light and moisture, and packaged in tamper-evident alu-alu blisters to maintain product integrity even under tropical storage conditions.

VORIFUNG 200 offers a favorable pharmacokinetic profile with high oral bioavailability, extensive tissue penetration, and predictable plasma concentration levels. However, therapeutic drug monitoring may be advised in long-term use or in patients with hepatic impairment, as Voriconazole is metabolized predominantly by the CYP2C19 pathway. BluepillExpress provides full regulatory documentation for VORIFUNG including Certificate of Analysis (CoA), stability data, and DMF support for partners across regulated and semi-regulated markets.

The administration of VORIFUNG may be associated with side effects such as visual disturbances, photosensitivity reactions, liver enzyme elevations, or QT prolongation in susceptible individuals. Therefore, baseline liver function tests and ECG monitoring are advised for patients on prolonged therapy. It is contraindicated with certain drugs such as rifampicin, carbamazepine, and ergot derivatives due to significant drug interactions, and caution must be exercised with cyclosporine and tacrolimus.

VORIFUNG 200 Tablet is typically prescribed in loading doses followed by maintenance therapy depending on the type and severity of infection. In adults, a common regimen involves a 400 mg loading dose every 12 hours for the first 24 hours, followed by 200 mg every 12 hours thereafter. Pediatric dosing is based on body weight and is adjusted accordingly. The tablets should be taken at least one hour before or after meals to optimize absorption.

BluepillExpress supports global partners in private labeling, institutional supply, and tender participation by offering customization in packaging, branding, and distribution logistics. The company ensures that VORIFUNG 200 is compliant with global export regulations and can provide registration dossiers, stability data, and labeling as per the importing country's requirements.